Benzinga | Dec 14, 2020 08:13AM EST

Credit Suisse Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $156

Credit Suisse maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $162 to $156.